Market Closed -
Nasdaq
04:00:00 2024-05-31 pm EDT
|
5-day change
|
1st Jan Change
|
6.79
USD
|
+4.46%
|
|
+5.43%
|
+2.88%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
2,004
|
505.8
|
292.4
|
323.9
|
478.5
|
-
|
-
|
Enterprise Value (EV)
1 |
2,004
|
505.8
|
292.4
|
323.9
|
478.5
|
478.5
|
478.5
|
P/E ratio
|
-11.3
x
|
-5.86
x
|
-2.3
x
|
-2.75
x
|
-3.38
x
|
-3.04
x
|
-2.54
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
46.9
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
46.9
x
|
EV / EBITDA
|
-
|
-5.97
x
|
-2.51
x
|
-2.57
x
|
-3.9
x
|
-3.81
x
|
-3.54
x
|
EV / FCF
|
-39.3
x
|
-6.93
x
|
-2.81
x
|
-2.83
x
|
-4.78
x
|
-3.32
x
|
-2.53
x
|
FCF Yield
|
-2.55%
|
-14.4%
|
-35.6%
|
-35.3%
|
-20.9%
|
-30.1%
|
-39.5%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
32,595
|
32,949
|
48,814
|
49,072
|
70,468
|
-
|
-
|
Reference price
2 |
61.47
|
15.35
|
5.990
|
6.600
|
6.790
|
6.790
|
6.790
|
Announcement Date
|
3/25/21
|
3/17/22
|
3/16/23
|
3/21/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
10.2
|
EBITDA
1 |
-
|
-
|
-84.67
|
-116.3
|
-125.8
|
-122.8
|
-125.4
|
-135
|
EBIT
1 |
-
|
-51.51
|
-86.43
|
-119
|
-131.6
|
-132.9
|
-148.4
|
-180.3
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-1,767.5%
|
Earnings before Tax (EBT)
1 |
-
|
-91.36
|
-86.08
|
-113.8
|
-117.5
|
-118.2
|
-136.5
|
-169
|
Net income
1 |
-21.08
|
-91.36
|
-86.08
|
-113.8
|
-117.5
|
-118.2
|
-140.4
|
-164
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-1,607.67%
|
EPS
2 |
-3.890
|
-5.440
|
-2.620
|
-2.610
|
-2.400
|
-2.010
|
-2.231
|
-2.670
|
Free Cash Flow
1 |
-
|
-51.02
|
-72.95
|
-104.1
|
-114.3
|
-100
|
-144
|
-189
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-1,852.94%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
6/19/20
|
3/25/21
|
3/17/22
|
3/16/23
|
3/21/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-
|
-25.49
|
-26.98
|
-29.6
|
-34.25
|
-33.52
|
-36.02
|
-27.31
|
-28.93
|
-30.51
|
-30.63
|
-30.76
|
-30.89
|
-31.16
|
-31.29
|
EBIT
1 |
-22.89
|
-26.1
|
-27.61
|
-30.26
|
-34.98
|
-34.31
|
-36.86
|
-29.29
|
-31.18
|
-32.76
|
-32.48
|
-32.77
|
-34.87
|
-31.96
|
-32.02
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-22.81
|
-25.99
|
-26.92
|
-28.34
|
-32.58
|
-30.82
|
-33.29
|
-25.64
|
-27.75
|
-29.52
|
-28.54
|
-28.95
|
-31.24
|
-29.34
|
-29.39
|
Net income
1 |
-22.81
|
-25.99
|
-26.92
|
-28.34
|
-32.58
|
-30.82
|
-33.29
|
-25.64
|
-27.75
|
-29.52
|
-28.54
|
-28.95
|
-31.24
|
-29.34
|
-29.39
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.6900
|
-0.7900
|
-0.6100
|
-0.5800
|
-0.6700
|
-0.6300
|
-0.6800
|
-0.5200
|
-0.5700
|
-0.5800
|
-0.4717
|
-0.4800
|
-0.4867
|
-0.5267
|
-0.5267
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/17/22
|
5/12/22
|
8/11/22
|
11/9/22
|
3/16/23
|
5/11/23
|
8/10/23
|
11/9/23
|
3/21/24
|
5/9/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-51
|
-73
|
-104
|
-114
|
-100
|
-144
|
-189
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
7.51
|
5.03
|
47.1
|
28.1
|
1.09
|
3
|
4
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
39.22%
|
Announcement Date
|
6/19/20
|
3/25/21
|
3/17/22
|
3/16/23
|
3/21/24
|
-
|
-
|
-
|
Last Close Price
6.79
USD Average target price
19.29
USD Spread / Average Target +184.03% Consensus |
1st Jan change
|
Capi.
|
---|
| +2.88% | 478M | | +11.91% | 118B | | +11.60% | 106B | | -4.68% | 24.28B | | -0.82% | 21.96B | | -10.12% | 18.16B | | -42.12% | 16.37B | | -17.47% | 15.56B | | +2.77% | 13.63B | | +34.58% | 12.27B |
Bio Therapeutic Drugs
|